{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:47:16Z","timestamp":1760298436390},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,12,15]],"date-time":"2011-12-15T00:00:00Z","timestamp":1323907200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s12032-011-0136-1","type":"journal-article","created":{"date-parts":[[2011,12,14]],"date-time":"2011-12-14T14:39:57Z","timestamp":1323873597000},"page":"2212-2219","source":"Crossref","is-referenced-by-count":12,"title":["Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study"],"prefix":"10.1007","volume":"29","author":[{"given":"Milena","family":"Todorovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bela","family":"Balint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bosko","family":"Andjelic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejana","family":"Stanisavljevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada Kraguljac","family":"Kurtovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziv","family":"Radisavljevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biljana","family":"Mihaljevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,12,15]]},"reference":[{"key":"136_CR1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"NL Harris","year":"1994","unstructured":"Harris NL, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361\u201392.","journal-title":"Blood"},{"key":"136_CR2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood.V78.2.259.bloodjournal782259","volume":"78","author":"M Raffeld","year":"1991","unstructured":"Raffeld M, Jaffe ES. Bcl\u20131, t (11; 14), and mantle cell-derived lymphomas. Blood. 1991;78:259\u201363.","journal-title":"Blood"},{"key":"136_CR3","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1080\/10428190410001723331","volume":"45","author":"E Matutes","year":"2004","unstructured":"Matutes E, et al. The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients. Leukemia Lymphoma. 2004;45:2007\u201315.","journal-title":"Leukemia Lymphoma"},{"key":"136_CR4","first-page":"115","volume":"36","author":"E Campo","year":"1999","unstructured":"Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol. 1999;36:115\u201327.","journal-title":"Semin Hematol"},{"key":"136_CR5","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1182\/blood.V87.11.4483.bloodjournal87114483","volume":"87","author":"DD Weisenburger","year":"1996","unstructured":"Weisenburger DD, Armitage JO. Mantle cell lymphoma; an entity comes of age. Blood. 1996;87:4483\u201394.","journal-title":"Blood"},{"key":"136_CR6","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"M Shipp","year":"1993","unstructured":"Shipp M, et al. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987\u201394.","journal-title":"N Engl J Med"},{"key":"136_CR7","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, et al. A new prognostic index (MIPI) for patients with advanced mantle cell lymphoma. Blood. 2008;111:558\u201365.","journal-title":"Blood"},{"key":"136_CR8","first-page":"877","volume":"10","author":"G Rothe","year":"1996","unstructured":"Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia. 1996;10:877\u201395.","journal-title":"Leukemia"},{"key":"136_CR9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/cyto.b.20363","volume":"72B","author":"BL Wood","year":"2007","unstructured":"Wood BL, et al. 2006 Bethesda international consensus recommendation on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: oprimal reagents and reporting for the flow cytometric diagnosis of hematopoietic heoplasia. Cytom Part B (Clin Cytom). 2007;72B:14\u201322.","journal-title":"Cytom Part B (Clin Cytom)"},{"key":"136_CR10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/00365516809076979","volume":"21","author":"A Boyum","year":"1968","unstructured":"Boyum A, et al. Separation of leucocytes from blood and bone marrow. Scand J Clin Lab Invest. 1968;21:77\u201389.","journal-title":"Scand J Clin Lab Invest"},{"key":"136_CR11","first-page":"378","volume":"108","author":"EJ Moreau","year":"1997","unstructured":"Moreau EJ, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Hematopathology. 1997;108:378\u201382.","journal-title":"Hematopathology"},{"key":"136_CR12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.beha.2010.01.001","volume":"23","author":"E Matutes","year":"2010","unstructured":"Matutes E, Attygalle A, Wotherspoon A, Catovsky D. Diagnostic issues in chronic lymphocytic leukemia (CLL). Best Pract Res Clin Hematol. 2010;23:3\u201320.","journal-title":"Best Pract Res Clin Hematol"},{"key":"136_CR13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1023\/A:1008309405678","volume":"11","author":"JM Foran","year":"2000","unstructured":"Foran JM, et al. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol. 2000;11:117\u201321.","journal-title":"Ann Oncol"},{"key":"136_CR14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","volume":"23","author":"M Ghielmini","year":"2005","unstructured":"Ghielmini M, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2005;23:705\u201311.","journal-title":"J Clin Oncol"},{"key":"136_CR15","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","volume":"114","author":"M Ghielmini","year":"2009","unstructured":"Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood. 2009;114:1469\u201376.","journal-title":"Blood"},{"key":"136_CR16","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","volume":"20","author":"OM Howard","year":"2002","unstructured":"Howard OM, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol. 2002;20:1288\u201394.","journal-title":"J Clin Oncol"},{"key":"136_CR17","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","volume":"99","author":"H Schulz","year":"2007","unstructured":"Schulz H, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99:706\u201314.","journal-title":"J Natl Cancer Inst"},{"key":"136_CR18","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","volume":"115","author":"CH Geisler","year":"2010","unstructured":"Geisler CH, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010;115:1530\u20133.","journal-title":"Blood"},{"key":"136_CR19","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","volume":"111","author":"O Determann","year":"2008","unstructured":"Determann O, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008;111:2385\u20137.","journal-title":"Blood"},{"key":"136_CR20","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2005-10-4079","volume":"107","author":"T Katzenberger","year":"2006","unstructured":"Katzenberger T, et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood. 2006;107:3407.","journal-title":"Blood"},{"key":"136_CR21","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/sj.bjc.6602795","volume":"93","author":"C Schrader","year":"2005","unstructured":"Schrader C, et al. Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma. Br J Cancer. 2005;93:939\u201345.","journal-title":"Br J Cancer"},{"key":"136_CR22","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1600-0609.2005.00540.x","volume":"75","author":"C Schrader","year":"2005","unstructured":"Schrader C, et al. Repp 86: a new prognostic marker in mantle cell lymphoma. Eur J Haematol. 2005;75:498\u2013504.","journal-title":"Eur J Haematol"},{"key":"136_CR23","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/sj.leu.2403387","volume":"18","author":"C Schrader","year":"2004","unstructured":"Schrader C, et al. Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia. 2004;18:1200\u20136.","journal-title":"Leukemia"},{"key":"136_CR24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","volume":"131","author":"M Tiemann","year":"2005","unstructured":"Tiemann M, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 2005;131:29\u201338.","journal-title":"Br J Haematol"},{"key":"136_CR25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/annonc\/mdp495","volume":"21","author":"R Schaffel","year":"2010","unstructured":"Schaffel R, et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol. 2010;21:133\u20139.","journal-title":"Ann Oncol"},{"key":"136_CR26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0609.2002.01677.x","volume":"69","author":"R R\u00e4ty","year":"2002","unstructured":"R\u00e4ty R, et al. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol. 2002;69:11\u201320.","journal-title":"Eur J Haematol"},{"key":"136_CR27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/1042819021000035653","volume":"44","author":"CH Wohlschlaeger","year":"2003","unstructured":"Wohlschlaeger CH, Lange HM, Feller AC. Aberrant immunophenotypes of mantle cell lymphomas. Leukemia Lymphoma. 2003;44:269\u201373.","journal-title":"Leukemia Lymphoma"},{"key":"136_CR28","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.5858\/2008-132-1346-AUCOMC","volume":"132","author":"V Sriganeshan","year":"2008","unstructured":"Sriganeshan V, Blom TR, Weissmann DJ. A unique case of mantle cell lymphoma with an aberrant CD5\/CD10 immunophenotype and typical morphology. Arch Pathol Lab Med. 2008;132:1346\u20139.","journal-title":"Arch Pathol Lab Med"},{"key":"136_CR29","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23:3383\u20139.","journal-title":"J Clin Oncol"},{"key":"136_CR30","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","volume":"23","author":"OA O\u2019Connor","year":"2005","unstructured":"O\u2019Connor OA, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676\u201384.","journal-title":"J Clin Oncol"},{"key":"136_CR31","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867\u201374.","journal-title":"J Clin Oncol"},{"key":"136_CR32","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23:5347\u2013456.","journal-title":"J Clin Oncol"},{"key":"136_CR33","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","volume":"26","author":"PH Wiernik","year":"2008","unstructured":"Wiernik PH, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008;26:4952\u20137.","journal-title":"J Clin Oncol"},{"key":"136_CR34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s12032-007-0029-5","volume":"24","author":"M Todorovic","year":"2007","unstructured":"Todorovic M, et al. Immunophenotypic profile and clinical characteristics in patients with advanced stage mantle cell lymphoma. Med Oncol. 2007;24:413\u20138.","journal-title":"Med Oncol"},{"key":"136_CR35","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1097\/01.pas.0000208899.15859.cb","volume":"30","author":"A Salar","year":"2006","unstructured":"Salar A, et al. Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am J Surg Pathol. 2006;30:1274\u201380.","journal-title":"Am J Surg Pathol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-011-0136-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-011-0136-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-011-0136-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T05:33:49Z","timestamp":1639978429000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-011-0136-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,15]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["136"],"URL":"https:\/\/doi.org\/10.1007\/s12032-011-0136-1","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,15]]}}}